SCHEMBL5831702

SCHEMBL5831702

CCN(C)C(=O)Cc1nsc(NS(=O)(=O)c2c(Cl)cc(Cl)cc2Cl)n1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.41
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 7/20 0.37
MEN1 O00255 6/20 0.37
KDM4E B2RXH2 5/20 0.37
MAPT P10636 2/20 0.37
ALDH1A1 P00352 7/20 0.36
POLB P06746 1/20 0.36
HSD17B1 P14061 1/20 0.35
HSD17B2 P37059 1/20 0.35
LMNA P02545 3/20 0.35
NPSR1 Q6W5P4 1/20 0.34
SLC40A1 Q9NP59 1/20 0.34
CRHR1 P34998 1/20 0.34
HTT P42858 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5831130 0.94 HSD11B1 (0.37) HSD11B1NPC1RAB9AKMT2AMEN1
SCHEMBL5830977 0.90 HSD11B1 (0.44) HSD11B1NPC1RAB9AKMT2AMEN1
SCHEMBL6930698 0.88 HSD11B1 (0.47) HSD11B1NPC1RAB9AKMT2AMEN1
SCHEMBL5830785 0.86 HSD11B1 (0.42) HSD11B1NPC1RAB9AKMT2AMEN1
SCHEMBL6929888 0.85 HSD11B1 (0.43) HSD11B1NPC1RAB9AKMT2AMEN1
SCHEMBL5831380 0.84 HSD11B1 (0.43) HSD11B1NPC1RAB9AKMT2AMEN1
SCHEMBL3615278 0.82 HSD11B1 (0.59) HSD11B1KMT2AMEN1MAPTALDH1A1
SCHEMBL27622959 0.81 NPC1 (0.35) HSD11B1NPC1RAB9AKMT2AMEN1
SCHEMBL5831647 0.81 HSD11B1 (0.58) HSD11B1KMT2AMEN1KDM4EALDH1A1
SCHEMBL5831943 0.80 KMT2A (0.44) HSD11B1KMT2AMEN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 HSD11B1 2/4885NPC1 471/4885RAB9A 2519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.